Brodimoprim (Ro-105970) is an analogue of trimethoprim and is an orally bioactive and long-acting DHFR/dihydrofolate reductase inhibitor with activity against a broad spectrum of gram-negative and gram-positive bacteria.
Physicochemical Properties
| Molecular Formula | C13H15N4O2BR |
| Molecular Weight | 339.1878 |
| Exact Mass | 338.037 |
| Elemental Analysis | C, 46.03; H, 4.46; Br, 23.56; N, 16.52; O, 9.43 |
| CAS # | 56518-41-3 |
| PubChem CID | 68760 |
| Appearance | Solid powder |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 563.8±60.0 °C at 760 mmHg |
| Melting Point | 225-228° |
| Flash Point | 294.7±32.9 °C |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.646 |
| LogP | 1.43 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 20 |
| Complexity | 296 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | COC1=C(C(=CC(=C1)CC2=CNC(=N)NC2=N)OC)Br |
| InChi Key | BFCRRLMMHNLSCP-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C13H15BrN4O2/c1-19-9-4-7(5-10(20-2)11(9)14)3-8-6-17-13(16)18-12(8)15/h4-6H,3H2,1-2H3,(H4,15,16,17,18) |
| Chemical Name | 2,4-Diamino-5-(4-bromo-3,5-dimethoxybenzyl)pyrimidine |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1].Weidekamm E. Pharmacokinetics of brodimoprim. J Chemother. 1993;5(6):475-479. [2].Marchese A, et al. Brodimoprim: effects of subminimal inhibitory concentrations on virulence traits of respiratory and urinary tract pathogens, and on plasmid transfer and stability. J Chemother. 1996;8(3):171-177. |
| Additional Infomation | Brodimoprim is an aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group. It has a role as an EC 1.5.1.3 (dihydrofolate reductase) inhibitor, an antiinfective agent and an antibacterial drug. It is an aminopyrimidine, a member of bromobenzenes and a member of methoxybenzenes. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~33.33 mg/mL (~98.26 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 3: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (7.37 mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9482 mL | 14.7410 mL | 29.4820 mL | |
| 5 mM | 0.5896 mL | 2.9482 mL | 5.8964 mL | |
| 10 mM | 0.2948 mL | 1.4741 mL | 2.9482 mL |